Report cover image

Acne Vulgaris (AV) - Competitive Landscape

Publisher GlobalData
Published Apr 15, 2024
Length 85 Pages
SKU # GBDT18789310

Description

Acne Vulgaris (AV) - Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in AV therapeutics.
  • GlobalData epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV.
  • Topical retinoids and topical antibiotics are usually the first-line therapy for mild-to-moderate acne.
  • The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline.
  • The US is emerging as the key country for conducting AV trials.
  • Acquisition was the most prevalent deal type in North America, Asia-Pacific, and Europe.
Scope

GlobalData’s AV: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the AV market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AV market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

85 Pages
  • Report Scope
  • Abbreviations
  • Key Findings
    • Disease Etiology
    • Epidemiology Overview - Diagnosed Prevalent Cases of AV in 2023 and 2026
    • Treatment Guidelines
    • Management Algorithm - Suggested Management Regimens
    • Marketed Drugs - Leading Marketed Drugs in AV
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drug Profile - Paratek Pharmaceutical's Seysara
    • Marketed Drug Profile - Journey Medical's Amzeeq
    • Marketed Drug Profile - Bausch Health's Cabtreo
    • Marketed Drug Profile - InfectoPharm's Clienzo
    • Marketed Drug Profile - Sol-Gel Technologies/Galderma's Twyneo
    • Marketed Drug Profile - Maruho's Bepio
    • Marketed Drug Profile - Cosmo Pharmaceuticals' Winlevi
    • Marketed Drug Profile - Almirall/Chartwell Pharmaceutical's Acticlate
    • Marketed Drug Profile - GSK's Isotrex
    • Marketed Drug Profile - Ortho Dermatologics' Arazlo
    • Marketed Drug Profile - Galderma's Aklief
    • Marketed Drug Profile - Sun Pharmaceutical's Xyrosa/Tetradox
    • Marketed Drugs - Average Cost of Therapy for AV
    • Marketed Drugs - Time to Pricing and Reimbursement
    • Pipeline Drugs Overview - Late-Stage Pipeline Drugs in AV
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - PTSR and LoA in AV
    • Pipeline Drugs - PTSR and LoA in Dermatology and AV
    • Clinical Trials in AV - Historical Overview
    • Clinical Trials in AV - Overview by Phase
    • Clinical Trials in AV - Overview by Status
    • Clinical Trials in AV - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in AV - Trials with a Virtual Component
    • Clinical Trials in AV - Geographic Overview
    • Clinical Trials in AV - Single-Country and Multinational Trials by Region
    • Clinical Trials in AV - Top Sponsors with Breakdown by Phase
    • Clinical Trials in AV - Top Sponsors with Breakdown by Status
    • Clinical Trials in AV - Overview by Endpoint Status
    • Clinical Trials in AV - Overview by Race and Ethnicity
    • Clinical Trials in AV - Enrollment Data
    • Clinical Trials in AV - Overview of Sites by Geography
    • Clinical Trials in AV - Top 20 Countries for Trial Sites
    • Clinical Trials in AV - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for AV
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in AV by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in AV
    • Commercial Assessment - Key Market Players in AV
    • Future Market Catalysts - Upcoming Market Catalysts in AV
    • Methodology - Sales Forecasts
    • Methodology
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.